8-methoxypsoralen and long ultraviolet effects on the rat lens: experiments with high dosage. 1982

H R Koch, and R Beitzen, and F Kremer, and G Chioralia, and H Baurmann, and J Megaw, and K Gardner, and S Lerman

The effect of systemic 8-methoxypsoralen (8-MOP; 100 mg/kg daily) and subsequent long ultraviolet irradiation (UVA; 300 mJ/cm2; peak: 365 nm) on albino and pigmented rat eyes was studied in a 3-dimensional experimental set-up. While 8-MOP and UVA did not cause any ocular pathology when administered alone, a combined application of the two factors caused reversible corneal opacities, and irreversible iris devascularisation and cataracts. The irreversible changes were seen only in the albinos and accompanied by a significant decrease in lens wet weight. Phosphorescence and EPR spectroscopy demonstrated the formation of an 8-MOP-protein photoadduct in the animals treated with both 8-MOP and UVA. The results of this study emphasize the necessity of shielding the eyes of patients on photochemotherapy with protective spectacles.

UI MeSH Term Description Entries
D007908 Lens, Crystalline A transparent, biconvex structure of the EYE, enclosed in a capsule and situated behind the IRIS and in front of the vitreous humor (VITREOUS BODY). It is slightly overlapped at its margin by the ciliary processes. Adaptation by the CILIARY BODY is crucial for OCULAR ACCOMMODATION. Eye Lens,Lens, Eye,Crystalline Lens
D008730 Methoxsalen A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation. 8-Methoxypsoralen,Ammoidin,Xanthotoxin,8-MOP,Deltasoralen,Dermox,Geroxalen,Meladinina,Meladinine,Meloxine,Methoxa-Dome,Méladinine,Oxsoralen,Oxsoralen-Ultra,Puvalen,Ultramop,8 MOP,8 Methoxypsoralen,8MOP,Methoxa Dome,Oxsoralen Ultra
D009929 Organ Size The measurement of an organ in volume, mass, or heaviness. Organ Volume,Organ Weight,Size, Organ,Weight, Organ
D010778 Photochemotherapy Therapy using oral or topical photosensitizing agents with subsequent exposure to light. Blue Light Photodynamic Therapy,Photodynamic Therapy,Red Light PDT,Red Light Photodynamic Therapy,Therapy, Photodynamic,Light PDT, Red,PDT, Red Light,Photochemotherapies,Photodynamic Therapies,Therapies, Photodynamic
D011701 PUVA Therapy Photochemotherapy using PSORALENS as the photosensitizing agent and ultraviolet light type A (UVA). Psoralen Ultraviolet A Therapy,Therapy, PUVA,PUVA Therapies,Therapies, PUVA
D002386 Cataract Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed) Cataract, Membranous,Lens Opacities,Pseudoaphakia,Cataracts,Cataracts, Membranous,Lens Opacity,Membranous Cataract,Membranous Cataracts,Opacities, Lens,Opacity, Lens,Pseudoaphakias
D003318 Corneal Opacity Disorder occurring in the central or peripheral area of the cornea. The usual degree of transparency becomes relatively opaque. Leukoma,Corneal Opacities,Leukomas,Opacities, Corneal,Opacity, Corneal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005128 Eye Diseases Diseases affecting the eye. Eye Disorders,Eye Disease,Eye Disorder
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

H R Koch, and R Beitzen, and F Kremer, and G Chioralia, and H Baurmann, and J Megaw, and K Gardner, and S Lerman
September 1977, Nippon Ganka Gakkai zasshi,
H R Koch, and R Beitzen, and F Kremer, and G Chioralia, and H Baurmann, and J Megaw, and K Gardner, and S Lerman
September 1976, Ugeskrift for laeger,
H R Koch, and R Beitzen, and F Kremer, and G Chioralia, and H Baurmann, and J Megaw, and K Gardner, and S Lerman
February 1995, Biochemical and biophysical research communications,
H R Koch, and R Beitzen, and F Kremer, and G Chioralia, and H Baurmann, and J Megaw, and K Gardner, and S Lerman
October 1981, The Journal of investigative dermatology,
H R Koch, and R Beitzen, and F Kremer, and G Chioralia, and H Baurmann, and J Megaw, and K Gardner, and S Lerman
July 1976, Nederlands tijdschrift voor geneeskunde,
H R Koch, and R Beitzen, and F Kremer, and G Chioralia, and H Baurmann, and J Megaw, and K Gardner, and S Lerman
October 1982, International journal of dermatology,
H R Koch, and R Beitzen, and F Kremer, and G Chioralia, and H Baurmann, and J Megaw, and K Gardner, and S Lerman
January 1989, The Journal of investigative dermatology,
H R Koch, and R Beitzen, and F Kremer, and G Chioralia, and H Baurmann, and J Megaw, and K Gardner, and S Lerman
August 1981, Nippon Ganka Gakkai zasshi,
H R Koch, and R Beitzen, and F Kremer, and G Chioralia, and H Baurmann, and J Megaw, and K Gardner, and S Lerman
March 1961, The Journal of pharmacology and experimental therapeutics,
H R Koch, and R Beitzen, and F Kremer, and G Chioralia, and H Baurmann, and J Megaw, and K Gardner, and S Lerman
April 1958, Science (New York, N.Y.),
Copied contents to your clipboard!